Krishnamohan Neha 4
4 · Kinnate Biopharma Inc. · Filed Apr 5, 2024
Insider Transaction Report
Form 4
Krishnamohan Neha
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2024-04-03−185,000→ 0 totalExercise: $10.03Exp: 2032-02-11→ Common Stock (185,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2024-04-03−215,000→ 0 totalExercise: $6.78Exp: 2033-02-10→ Common Stock (215,000 underlying) - Disposition to Issuer
Common Stock
2024-04-03−64,087→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2024-04-03−270,000→ 0 totalExercise: $23.26Exp: 2031-06-07→ Common Stock (270,000 underlying)
Footnotes (3)
- [F1]Includes 42,188 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.
- [F2]Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR.
- [F3]This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.